What is the 13F Pro Quality Score for CBLL?

13F Pro ranks Ceribell, Inc. (CBLL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CBLL's current score at https://13fpro.ai/research/CBLL (free sign-up required for the full ranking).

Which hedge funds own the most CBLL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CBLL include FMR, TPG GP A,, Red Tree Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CBLL as soon as new 13F filings post.

Where does 13F Pro source CBLL data?

All Ceribell, Inc. fundamentals and ownership data come directly from SEC EDGAR. Ceribell, Inc. files with the SEC under CIK 1861107. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CBLL in?

Ceribell, Inc. (CBLL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CBLL research updated on 13F Pro?

CBLL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ceribell, Inc.(CBLL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1861107 CBLL stock profile & AI dashboard →

13F Pro Quality Score

32.1/100

Rank #2,284 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

94.6/100

Profitability

9.3/100

Balance Sheet

7.4/100

Earnings Quality

30.0/100

Free Cash Flow

8.9/100

Institutional Flow

84.5/100

Revenue Scale

16.5/100

Dilution Risk

13.3/100

CBLL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ceribell, Inc. (CBLL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CBLL at 32.1/100 on a 32-signal composite quality model, placing it at rank #2,284 of 2,879 stocks — the bottom half of the AI-ranked universe. CBLL scores in the top quartile across revenue growth (94.6), institutional flow (84.5). Areas of concern include balance sheet strength (7.4) and free cash flow (8.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Ceribell, Inc. reports quarterly revenue of $26.5M, net income of $-19.7M, an operating margin of -78.3%. Top institutional holders of CBLL by reported 13-F value include FMR, TPG GP A,, Red Tree Management,, based on the most recent SEC filings. CBLL trades on the Nasdaq exchange and files with the SEC under CIK 1861107. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CBLL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ceribell, Inc. directly from SEC EDGAR. Ceribell, Inc.'s 13F Pro composite quality score has ranged between 29 and 40 since 2025, currently 32.1 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about Ceribell, Inc.

Quirks, history, and lore behind CBLL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Revenue in the tens of millions annually — it's an early-stage commercial company burning cash to grow, with a market cap well under $1 billion.
3
The History
Founded in the 2010s, it spent years in development before going public, targeting a market where brain monitoring had long been stuck in the ICU dark ages.
4
The Secret
Its core product straps around a patient's head like a headband and delivers continuous EEG monitoring — no neurologist required to set it up, no gel, no fuss.
5
The Lore
The company targets non-convulsive seizures — the silent kind that don't look like seizures at all — which are dangerously underdetected in ICU and emergency settings.
6
The Giveaway
Its flagship device is called the Clarity System — a rapid-setup EEG headband designed to catch brain seizures at the bedside, made by a company whose ticker nods to the brain itself.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$26.5M

Net Income

Q1 2026

$-19.7M

Free Cash Flow

Q1 2026

$-19.4M

Operating Margin

Q1 2026

-78.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+36.1% YoY

$89.1MFY 2025

FY23 $45.2MFY24 $65.4MFY25 $89.1M

Net Income

-32.0% YoY

$-53.4MFY 2025

FY23 $-29.5MFY24 $-40.5MFY25 $-53.4M

Operating Income

-47.1% YoY

$-58.4MFY 2025

FY23 $-30.0MFY24 $-39.7MFY25 $-58.4M

EPS (Diluted)

+56.9% YoY

$-1.46FY 2025

FY23 $-5.56FY24 $-3.39FY25 $-1.46

Total Assets

-13.1% YoY

$195.8MFY 2025

FY23 $58.9MFY24 $225.4MFY25 $195.8M

Op. Cash Flow

-16.5% YoY

$-40.8MFY 2025

FY23 $-29.2MFY24 $-35.0MFY25 $-40.8M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$89.1M +36.1%	$65.4M +44.7%	$45.2M
Net Income	$-53.4M -32.0%	$-40.5M -37.3%	$-29.5M
Operating Income	$-58.4M -47.1%	$-39.7M -32.2%	$-30.0M
EPS (Diluted)	$-1.46 +56.9%	$-3.39 +39.0%	$-5.56
Total Assets	$195.8M -13.1%	$225.4M +282.6%	$58.9M
Operating Cash Flow	$-40.8M -16.5%	$-35.0M -20.2%	$-29.2M

AI Insight: CBLL Financial Trends

Revenue grew 37% from Q4 2024 to Q1 2026, but a sharp loss spike in Q1 2026 signals mounting cost pressure that is rapidly eroding equity.

• Revenue rose steadily from $19M in Q4 2024 to $26M in Q1 2026, a 37% increase over five quarters.

• Operating loss widened sharply to $-21M in Q1 2026 from a relatively stable $-13M to $-15M range across prior quarters.

• Operating cash outflow surged to $-19M in Q1 2026, nearly double the $-10M to $-11M range seen in most prior quarters.

• Equity has declined every quarter from $191M in Q4 2024 to $141M in Q1 2026, a $50M erosion in five quarters.

⚠ The Q1 2026 jump in net loss to $-20M — from a stable $-13M to $-14M range — warrants scrutiny for one-time vs. structural cost drivers.

⚠ Equity runway: at the current burn rate, equity of $141M in Q1 2026 could deplete within a few years without additional capital raises.

⚠ Total debt data is absent across all periods; disclosure of leverage would materially change the balance-sheet risk picture.

AI Insight: CBLL Ratio Trends

Q1 2026 marks a sharp deterioration across all metrics, reversing two consecutive quarters of margin improvement.

• Operating margin worsened sharply to -78.3% in Q1 2026 from -58.9% in Q4 2025, erasing prior sequential gains.

• Net profit margin fell to -74.5% in Q1 2026 from -54.6% in Q4 2025, the worst reading in the visible history.

• Operating margin had improved from -70.5% in Q2 2025 to -58.9% in Q4 2025 across two quarters before reversing.

• ROIC deteriorated to -58.9% in Q1 2026 from -37.6% in Q4 2025, signaling worsening capital efficiency.

⚠ Q1 2026 seasonality or one-off charges may explain the spike; confirm whether Q2 2026 trends revert toward Q4 2025 levels.

⚠ ROA collapsed to -44.3% in Q1 2026 vs. -27.6% in Q4 2025 — deepening asset-level losses warrant close monitoring.

⚠ D/E data is entirely absent; inability to assess leverage leaves balance-sheet risk unquantified.

Get alerted when CBLL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ceribell, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CBLL

FMR LLC
$88.9M4,850,431 sh
TPG GP A, LLC
$72.7M3,967,422 sh
Red Tree Management, LLC
$40.4M2,205,661 sh
BlackRock, Inc.
$33.2M1,813,155 sh
KCM Capital Inc
$25.7M1,400,000 sh
Bank of New York Mellon Corp
$21.3M1,160,767 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.8M1,137,132 sh
FEDERATED HERMES, INC.
$17.2M939,464 sh
FRANKLIN RESOURCES INC
$14.8M809,514 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$13.9M756,751 sh

Fund	Value	Shares
FMR LLC	$88.9M	4,850,431
TPG GP A, LLC	$72.7M	3,967,422
Red Tree Management, LLC	$40.4M	2,205,661
BlackRock, Inc.	$33.2M	1,813,155
KCM Capital Inc	$25.7M	1,400,000
Bank of New York Mellon Corp	$21.3M	1,160,767
VANGUARD CAPITAL MANAGEMENT LLC	$20.8M	1,137,132
FEDERATED HERMES, INC.	$17.2M	939,464
FRANKLIN RESOURCES INC	$14.8M	809,514
ADAGE CAPITAL PARTNERS GP, L.L.C.	$13.9M	756,751

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CBLL on your watchlist

Track score changes the day Ceribell, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CBLL a good stock to buy?

13F Pro's AI-powered analysis of Ceribell, Inc. (CBLL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CBLL are available on the CBLL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CBLL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CBLL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ceribell, Inc.'s investment landscape.